Best Immunotherapy Companies in Canada
The 55 best Immunotherapy companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: ProMIS Neurosciences.
- The Business Research Company
- ResearchAndMarkets.com
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 5 mo ago | 7 | Neil Cashman Co-Founder | Public | Top 10M | 78 patents Therapeutic antibodies targeting misfolded neurodegeneration proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 2 | Fusion Pharmaceuticals Developer of targeted alpha therapeutics for the treatment of cancers | $171M | 78 mo ago | 106 | — | Acquired | Top 10M | 294 patents Patents concentrated in health & consumer products | — |
| 3 | Zymeworks Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 30 mo ago | 277 277 → 271 (-2%) | — | Public | Top 5M | 1,015 patents Design and production of bispecific/trispecific recombinant antibody therapeutics targeting cancer antigens. | — |
| 4 | Trillium Therapeutics Developer of therapeutics for the treatment of cancer | $102M | 70 mo ago | 33 | — | Acquired | — | 180 patents Immune checkpoint therapies targeting CD47 with antibody and combination strategies | — |
| 5 | Bellus Health Developer of drugs for treating rare diseases | $71M | 89 mo ago | 13 | — | Acquired | — | 107 patents Patents concentrated in health & consumer products | — |
| 6 | OncoQuest Developing tumor antigen-specific monoclonal IgE antibodies for combinatorial immunotherapy | $69M | 76 mo ago | 9 | — | Series B | — | 21 patents Targeted monoclonal antibody cancer therapies combined with immune adjuvants and delivery enhancers | — |
| 7 | Medicago Developer of vaccines to treat pandemic and seasonal influenza | $50M | 177 mo ago | 600 | Toshifumi Tada CEO | Acquired | — | 711 patents Plant-based virus-like particle production for influenza and other viral vaccines | — |
| 8 | Oncolytics Biotech Develops oncolytic viruses for use as cancer therapeutics 48Patents top 29%Product top 30%Funding top 31%News top 33% All 11 signals ▾Patentstop 29% Producttop 30% Fundingtop 31% Newstop 33% Innovationtop 41% Moattop 41% Growthtop 47% Techtop 47% Talentbottom 49% Marketbottom 38% Globalbottom 37% Patents: 450 patents matched (strict assignee match) · 6 filings since 2022 vs 40 in 2017-21 Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 48/100 | $48M | 15 mo ago | 29 | Matt Coffey President and Chief Executive Officer | Public | Top 10M | 435 patents Engineering oncolytic viruses and delivery formulations for cancer immunotherapy | — |
| 9 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 22 mo ago | 11 | — | Series A | Top 50M | 38 patents Engineered multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 10 | KisoJi Developer of multi-specific antibodies for cancer treatment | $41M | 21 mo ago | — | David Young Co-Founder & CEO | Series B | — | — | — |
| 11 | 3T Biosciences Developer of T-cell-based cancer immunotherapies to fight cancer | $40M | 46 mo ago | 33 | Leah Sibener Co-Founder | Series A | Top 10M | 27 patents High‑density EGFR/ErbB2‑targeted antibodies for cancer diagnostics and therapy | — |
| 12 | Northern Biologics Developing antibody therapeutics for cancer and fibrosis | $40M | 134 mo ago | 21 | — | Acqui-Hired | — | 2 patents Patents concentrated in health & consumer products | — |
| 13 | Tetra Bio-Pharma Developer of natural medicinal plant-based elements for treating multiple diseases 32Funding top 26%Talent bottom 49%Market bottom 41%Tech bottom 38% All 6 signals ▾Fundingtop 26% Talentbottom 49% Marketbottom 41% Techbottom 38% Globalbottom 36% Newsbottom 24% Funding: Raised $37.9M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 32/100 | $38M | 40 mo ago | 33 | Andre Audet Co-Founder | Public | — | — | — |
| 14 | Qu Biologics Developing Site Specific Immunomodulators that aim to reboot the body's immune system to treat cancer and… | $30M | 51 mo ago | 22 | — | Series C | Top 50M | 80 patents Innate immune modulation for cell therapies, anti‑inflammatory and antimicrobial biologics | — |
| 15 | Arius Research Speciality company involved in discovery and development of antibody therapeutics for various cancer | $22M | 244 mo ago | 31 | David S Young Founder | Acquired | — | — | — |
| 16 | Alethia BioTherapeutics Developing monoclonal antibody-based therapeutics for cancer-associated diseases. | $14M | 21 mo ago | 12 | — | Series C | — | 205 patents Engineered peptide immunotherapies enhancing tumor-infiltrating lymphocyte infiltration. | — |
| 17 | Immune Biosolutions Recombinant antibodies for cancer, GI diseases. | $11M | 64 mo ago | 29 | — | Funding Raised | Top 50M | 16 patents Therapeutic antibodies against immune receptors and bacterial/toxin antigens for disease treatment | — |
| 18 | Viventia Bio Tumor targeting antibodies for patients suffering from cancer | $10M | 274 mo ago | — | Leslie Dan Founder | Acqui-Hired | — | 64 patents Therapeutic anti‑EPCAM antibodies and dosing regimens for EPCAM‑positive bladder cancer | — |
| 19 | Edesa Biotech Developer of topical therapeutics for dermatological and gastrointestinal diseases | $7M | 17 mo ago | 16 | Par Nijhawan Founder & CEO | Public | Top 10M | 8 patents Peptide-based therapeutics for vitiligo and acute respiratory distress syndrome | — |
| 20 | Vitaeris Monoclonal Antibodies (MAbs) for inflammatory diseases | $7M | 121 mo ago | 11 | — | Acquired | — | 31 patents Therapeutic anti‑IL‑6 antibodies for transplant desensitization and COVID‑19 ARDS treatment | — |
| 21 | Pattern Pharma Developer of immunotherapies to treat cancers and infectious diseases | $7M | 15 mo ago | 5 | — | Series A | — | — | — |
| 22 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 2 mo ago | — | John Bell Co-Founder | Seed | — | — | — |
| 23 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 53 mo ago | 2 | — | Series A | — | — | — |
| 24 | IntelliStem Developer of cell therapy medicine for cancer patient | $1M | 49 mo ago | — | Riam Shammaa Founder & CEO | Seed | — | — | — |
| 25 | Aurin Biotech Develops drugs that can block self-attack by the body’s complement system due to diseases | $795K | 98 mo ago | 2 | Patrick McGeer Co-Founder | Deadpooled | — | 44 patents Patents concentrated in health & consumer products | — |
| 26 | ImmunoFlex Developer of products to improve immunity | $500K | 65 mo ago | 2 | — | Seed | — | — | — |
| 27 | Avro Lifesciences Developer of dermal therapies and patches for pediatric use | $150K | 100 mo ago | 19 | — | Seed | — | — | — |
| 28 | Modulari-T Biosciences Developer of cell therapies for immune disorders | $125K | 37 mo ago | 5 | David White Co-Founder | Seed | Top 50M | — | 1 launch |
Top 12 Immunotherapy companies in Canada
#1
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
#2
Seed · Ottawa, Ontario · founded 2022$2.4Mraised▾
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- May 2026Seed$365.5K
- Jan 2025Seed$2M
- Dec 2024Grant (prize money)—
#3
Public · Calgary, Alberta · founded 1998 · 29 employees$48.1Mraised▾
Oncolytics Biotech is a development-stage biotechnology company that develops oncolytic viruses for use as cancer therapeutics. The company's leading product, REOLYSIN, is developed from the reovirus. Oncolytics Biotech claims that the virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The wholly owned subsidiaries of the Company include Oncolytics Biotech (Barbados) and Oncoltics Biotech (US).
- Apr 2025Post IPO$20M
- Oct 2010Post IPO$24M
- Post IPO$4.1M
#4
Series B · Montreal, Quebec · founded 2009$41.3Mraised▾
Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
- Oct 2024Series B$40.6M
- Jun 2018Series A—
- Oct 2016Seed$751.9K
#5
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
- Sep 2024Series A$35M
- Apr 2023Seed$8M
#6
Series A · Toronto, Ontario · founded 2018 · 5 employees$6.9Mraised▾
Pattern Pharma is developing immunotherapies to treat cancers and infectious diseases. Its lead candidate, PAR-1 modulates the innate immune system (dendritic cells, macrophages, and NK cells). The candidate is PRR (Pattern Recognition Receptor) TLR-4 agonist and is being tested a stand-alone product and in combination therapy.
- Apr 2025Series A$798.5K
- Feb 2024Series A$275K
- May 2021Series A$4.1M
- May 2021Seed$1.6M
#7
Public · Vancouver, British Columbia · founded 2003 · 277 employees$146Mraised▾
Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer. The company’s Azymetric and AlbuCORE platforms, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications.
- Dec 2023Post IPO$50M
- Jan 2016Series A$61.5M
- Feb 2015Series A$1.8M
- Jan 2015Series A$24M
#8
Public · Toronto, Ontario · founded 2015 · 16 employees$7Mraised▾
Developer of topical therapeutics for dermatological and gastrointestinal diseases. It is developing therapeutics for diseases such as contact dermatitis, hemorrhoids, and anal fissures. Its lead candidate, EB-01, is indicated for Allergic Contact Dermatitis and is already in Phase II clinical studies. The candidates in Phase I are EB-05, indicated for Irritant Contact Dermatitis, EB-02, for hemorrhoids, and EB-04, for Anal Fissures.
- Feb 2025Post IPO$15M
- Nov 2022Post IPO$3M
- Feb 2021Grant (prize money)—
- Sep 2017Post IPO$7M
#9
Series C · Montreal, Montreal · founded 2002 · 12 employees$13.9Mraised▾
Alethia Biotherapeutics engages in the discovery and development of therapeutic monoclonal antibodies (mAb) against highly-disease tissue-specific novel clinically-relevant targets. The company focuses on bone loss in acute disorders, invasive carcinomas, and cancer-associated epithelial-to-mesenchymal transition. Its products include AB-25E9, a bone antiresorptive and humanized IgG2 that inhibits the function of Siglec-15 and is used for the treatment of patients with acute bone loss; AB-3A4, an antibody-drug conjugate (ADC) representing a completely new therapeutic approach for treatment of invasive carcinomas; and AB-16B5, an humanized IgG2 monoclonal antibody and EMT inhibitor that targets tumor-associated secreted clusterins.
- Oct 2024Series C$5.1M
- Aug 2023Series C$6M
- Nov 2012Series B$4.7M
- Sep 2010Series A$9.2M
#10
Public · Ottawa, Ontario · founded 2015 · 33 employees$37.9Mraised▾
Developer of natural medicinal plant-based elements for treating multiple diseases. It engaged in the development of biopharmaceuticals and natural health products containing Cannabis and other medicinal plant-based elements. Its drug pipeline includes PPP001, a smokable bio-cannabis pharmaceutical for chronic pain, PPP002 to treat Insomnia, and PTSD in chronic pain patients, and PPP003 for chronic pain, PTSD, and other neurologic and psychiatric conditions. The company also develops natural health products for skin care, pain management, etc.
- Mar 2023Grant (prize money)—
- Aug 2022Post IPO—
- May 2022Post IPO$7.5M
- Jan 2021Post IPO$1.9M
#11
Acquired · Hamilton, Ontario · founded 2014 · 106 employees$170.9Mraised▾
Developer of targeted alpha therapeutics for the treatment of cancers. The company's product line include FPI-1434 combines the targeting of a human experienced antibody with Fusion’s linker technology and the alpha-emitting cytotoxic isotope Actinium-225 to induce cancer cell death. It is being developed for patients with solid tumors that internalize the insulin-like growth factor-1 receptor (IGF–1R), a rapidly internalizing membrane protein.
- Jan 2020Series B$19.9M
- Apr 2019Series B$105M
- Sep 2017Series A$21M
- Feb 2017Series A$25M
#12
Acquired · Toronto, Ontario · founded 1996 · 33 employees$101.9Mraised▾
Developer of therapeutics for the treatment of cancer. Its lead programs, SIRPaFc, and a CD200 monoclonal antibody (mAb), target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc which is entering phase I study is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. Its other clinical-stage programs include tigecycline which is being evaluated in a multi-center Phase I study in patients with AML and TTI-1612, which has been tested in a 28-patient Phase I trial in interstitial cystitis (IC) patients.
- Sep 2020Post IPO$25M
- Dec 2017Post IPO$20M
- 2017Post IPO—
- Jan 2014Post IPO$25.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth rising
How research on Immunology & Immunotherapy is moving in Canada
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,374 Canada-affiliated papers.
- Ministry of Education188
- Princess Margaret Cancer Centre97
- University of Toronto89
- McGill University78
- Institute of Cancer Research77
- Immune system6→142
- Cancer immunotherapy1→44
- Cancer2→39
- Cancer research1→37
- T cell2→29
- Immune system10→208
- Cancer3→88
- Tumor microenvironment1→74
- Cancer research6→63
- Internal medicine5→60
- Immune system4→74
- Cancer1→40
- Disease1→35
- Oncology3→27
- Chimeric antigen receptor1→22
Where immunology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in Canada
Canada immunology patent filing is cooling — 351 filings from 355 assignees (2016–2025), led by UNIV Health Network, UTI, UNIV British Columbia; annual filings 33→25.
- UNIV Health Network43
- UTI39
- UNIV British Columbia30
- Prometic Biosciences29
- Immunovaccine Technologies29
- UNIV Arkansas28
- UNIV Guelph26
- Texas A & M UNIV SYS26
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.